For patients already on monotherapy considering an upgrade, switching to GLP-Squared may feel more controlled and therapeutically intentional than adding a second injection
patients each month, and the agency should consider their role in alleviating the obesity drug supply crunch before barring them
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al
This may include people who: Are early in treatment Recently changed their dose Already have nausea, vomiting, reflux, diarrhea, or constipation Have trouble staying hydrated Have diabetes or take blood sugar-lowering medication Have a history of pancreatitis Have gallbladder disease or gallstones Have liver disease or abnormal liver enzymes Drink heavily or binge drink Have a history of alcohol use disorder Are pregnant, trying to become pregnant, or breastfeeding Are taking other medications that interact with alcohol If any of these apply to you, do not guess